Browse through a selection of publications related to Vascudyne’s tissues.
These are investigational uses that have not been approved by any health authority. Safety and efficacy have not been established and there is no guarantee that pipeline products or investigational uses will receive approval from health authorities.
Copyright 2025 | Vascudyne, Inc.
He founded the Cardiovascular Fluid Mechanics Laboratory at Georgia Tech in 1979, where he invented the science of prosthetic heart valve engineering—every prosthetic heart valve implanted in the U.S. has been studied and evaluated in his lab. Over a 45-year research career, he has mentored more than 50 doctoral students and 40 post-doctoral trainees while making profound contributions to native and artificial heart valves, congenital heart diseases, and minimally invasive cardiovascular interventions. He holds a Ph.D. in Chemical Engineering from the California Institute of Technology.
Academically trained in biology and chemistry Kem’s scientific career has focused primarily on the industrial research and development of Class III biomedical devices. His work career accomplishments include the invention, research, development and commercialization of a number of world class products, including Hemashield, the first collagen coated vascular conduit, PeriStrips, the first lung volume reduction staple line buttressing product, MitralSeal, the first transcatheter mitral valve prosthesis, and ArterX, a surgical sealant.
Chairman
Internationally renowned industrial manager and Chairman with long-standing track record (e.g. Chairman and CEO of Linde plc, management board member of BMW AG). Various transformational M&A transactions (e.g. merger of Linde and Praxair). Current supervisory board memberships: Continental AG (Chair), Axel Springer SE, Hawesko Holding AG, Ivoclar Vivadent AG. Long-standing growth equity investor and mentor for innovative companies across industries.
